The national and subnational burden of Hodgkin Lymphoma (HL) in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023
Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Lorenzo Monasta(IRCCS Materno Infantile Burlo Garofolo), Giulia Carreras(Meyer Children's Hospital), Caterina Ledda, Matteo Bauckneht(Azienda Ospedaliera S.Maria), Elisa Fabbro(University of Udine), Carlo La Vecchia(University of Milan), Giuseppe Minervini(Govt. Dental College & Hospital), Mihajlo Jakovljević(Shaanxi University of Technology), Giulia Zamagni
Cited by 1
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis
|Nature Communications|2020|694
Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC)
|Nutrition Metabolism and Cardiovascular Diseases|2015|691
The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet. Gastroenterology & hepatology|2019|668